Abstract
Epilepsy is the second most prevalent neurological disease worldwide. It is mainly characterized by an electrical abnormal activity in different brain regions. The massive entrance of Ca2+ into neurons is the main neurotoxic process that lead to cell death and finally to neurodegeneration. Although there are a huge number of antiseizure medications, there are many patients who do not respond to the treatments and present refractory epilepsy. In this context, nanomedicine constitutes a promising alternative to enhance the central nervous system bioavailability of antiseizure medications. The encapsulation of different chemical compounds at once in a variety of controlled drug delivery systems gives rise to an enhanced drug effectiveness mainly due to their targeting and penetration into the deepest brain region and the protection of the drug chemical structure. Thus, in this review we will explore the recent advances in the development of drugs associated with polymeric and lipid‐based nanocarriers as novel tools for the management of epilepsy disorders.
Highlights
Epilepsy is a chronic disease of the central nervous system (CNS) mainly characterized by an abnormal electrical activity of the neurons of hippocampus and cortex regions
Epilepsy is a neurological disease with high incidence that involves seizure episodes with serious consequences for the well-being and health of patients
| 9 problems that treatment with Antiseizure medications (ASM) present is the narrow therapeutic margin of these drugs as well as the resistance observed during long-term treatments
Summary
Epilepsy is a chronic disease of the central nervous system (CNS) mainly characterized by an abnormal electrical activity of the neurons of hippocampus and cortex regions. In order to improve the pharmacological treatment of epilepsy and reduce the number of patients with resistance to ASM and their adverse effects, in recent years, many efforts have been invested in order to be able to administer these drugs carried by PNP.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
